Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus

Bibliography

• International Diabetes Federation. Diabetes atlas. International Diabetes Federation Web site. Available from: www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition [Last accessed 31 October 2012]
   Google Scholar
• de Pablos-Velasco P, Bradley C, Eschwège E, The PANORAMA pan-European survey: glycaemic control and treatment patterns in patients with type 2 diabetes. Diabetologia 2010;53(Suppl 1):1012-P
   Google Scholar
• Wong K, Glovaci D, Malik S, Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification. J Diabetes Complications 2012;26(3):169-74
   PubMed Web of Science ®Google Scholar
• Whaley JM, Tirmenstein M, Reilly TP, Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2012;5:135-48
   PubMedGoogle Scholar
• Chao EC, Henry RR. SGLT2 inhibition–a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9(7):551-9
   PubMed Web of Science ®Google Scholar
• Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009;53(5):875-83
   PubMed Web of Science ®Google Scholar
• Guyton AC, Hall JE. Textbook of medical physiology. 11th edition. Elsevier, Inc, Philadelphia, PA; 2006
   Google Scholar
• Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008;62(8):1279-84
   PubMed Web of Science ®Google Scholar
• Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5(1):133-41
   PubMed Web of Science ®Google Scholar
• Barfuss DW, Schafer JA. Differences in active and passive glucose transport along the proximal nephron. Am J Physiol 1981;241(3):F322-32
   PubMed Web of Science ®Google Scholar
• Ikeda TS, Hwang ES, Coady MJ, Characterization of a Na+/glucose cotransporter cloned from rabbit small intestine. J Membr Biol 1989;110(1):87-95
   PubMed Web of Science ®Google Scholar
• Turner RJ, Silverman M. Sugar uptake into brush border vesicles from normal human kidney. Proc Natl Acad Sci USA 1977;74(7):2825-9
   PubMed Web of Science ®Google Scholar
• Turner RJ, Moran A. Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: evidence from vesicle studies. Am J Physiol 1982;242(4):F406-14
   PubMed Web of Science ®Google Scholar
• Turner RJ, Moran A. Further studies of proximal tubular brush border membrane D-glucose transport heterogeneity. J Membr Biol 1982;70(1):37-45
   PubMed Web of Science ®Google Scholar
• Uveges A, Hagan D, Onorato J, Dapagliflozin selectively inhibits human SGLT2 versus SGLT1, SMIT, SGLT4 and SGLT6 [abstract 987-P]. 71st Scientific Sessions of the American Diabetes Association; 24-28 June 2011; San Diego, CA
   Google Scholar
• Grempler R, Thomas L, Eckhardt M, Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14(1):83-90
   PubMed Web of Science ®Google Scholar
• Sabolic I, Skarica M, Gorboulev V, Rat renal glucose transporter SGLT1 exhibits zonal distribution and androgen-dependent gender differences. Am J Physiol Renal Physiol 2006;290(4):F913-26
   PubMed Web of Science ®Google Scholar
• Sabolic I, Vrhovac I, Eror DB, Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 2012;302(8):C1174-88
   PubMed Web of Science ®Google Scholar
• Chen J, Williams S, Ho S, Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010;1(2):57-92
   PubMedGoogle Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261(1):32-43
   PubMed Web of Science ®Google Scholar
• Zhou L, Cryan EV, D'Andrea MR, Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003;90(2):339-46
   PubMed Web of Science ®Google Scholar
• Rahmoune H, Thompson PW, Ward JM, Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54(12):3427-34
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14(6):782-90
   PubMedGoogle Scholar
• Freitas HS, Anhe GF, Melo KF, Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008;149(2):717-24
   PubMed Web of Science ®Google Scholar
• Osorio H, Bautista R, Rios A, Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract 2009;86(3):e46-9
   PubMed Web of Science ®Google Scholar
• Osorio H, Bautista R, Rios A, Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats. J Nephrol 2010;23(5):541-6
   PubMed Web of Science ®Google Scholar
• Vestri S, Okamoto MM, de Freitas HS, Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001;182(2):105-12
   PubMed Web of Science ®Google Scholar
• Tabatabai NM, Sharma M, Blumenthal SS, Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract 2009;83(1):e27-30
   PubMedGoogle Scholar
• Ghezzi C, Wright EM. Regulation of the human Na+-dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol 2012;303(3):C348-54
   PubMed Web of Science ®Google Scholar
• Guan B, Yang WP, Ma X, Transcription profiling analyses of male ZDF rat tissues following chronic dapagliflozin treatment. Diabetes 2011;60(Suppl):A312
   Google Scholar
• Ehrenkranz JR, Lewis NG, Kahn CR, Phlorizin: a review. Diabetes Metab Res Rev 2005;21(1):31-8
   PubMed Web of Science ®Google Scholar
• Achard C, Delamere V. The bark of the apple root, phlorizin, reduces diabetic hyperglycemia. Soc Medic Des Hopitaux 1899;379-93
   Google Scholar
• Rossetti L, Shulman GI, Zawalich W, Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80(4):1037-44
   PubMed Web of Science ®Google Scholar
• Rossetti L, Smith D, Shulman GI, Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79(5):1510-15
   PubMed Web of Science ®Google Scholar
• Asano T, Anai M, Sakoda H. SGLT as a therapeutic target. Drugs Future 2004;29:461-6
   Web of Science ®Google Scholar
• Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007;8(4):285-92
   PubMed Web of Science ®Google Scholar
• Washburn WN. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 2009;52(7):1785-94
   PubMed Web of Science ®Google Scholar
• Washburn WN. SGLT2 Inhibitors in development. In: Jones RM, Thurston DE, Rotella DP, et al., editors. New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. Royal Chemical Society 2012;29-87
   Google Scholar
• Fukuzawa T, Nagata T, Takeda M, Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves pancreatic and renal functions in animal models of type 2 diabetes [Abstract 1135-P]. 71st Scientific Sessions of the American Diabetes Association; 24-28 June 2011, San Diego, CA
   Google Scholar
• Ueta K, Torres PT, McCoy GL, Normalizaton of hyperglycemia by inhibiting SGLT2 prevents progressive reduction of hepatic glucokinase (GK) expression and improves hepatic glucose metabolism (HGM) in Zucker diabetic fatty (ZDF) rats [abstract 608-P]. 70th Scientific Session of the American Diabetes Association; 25-29 June 2010; Orlando, FL
   Google Scholar
• Zinker B, Ma X, Liu H, Chronic dapagliflozin treatment reduces elevated hepatic glucose production and enhances pancreatic insulin content in male ZDF rats. Diabetes 2011;60(Suppl):A283
   Google Scholar
• Teisuke T, Kozakai A, Kojima N, Long-term treatment of TS-071, a novel and selective SGLT2 inhibitor, improves hyperglycemia and prevents loss of b-cell in diabetic mice [abstract 845]. 47th Annual Meeting of the European Association for the Study of Diabetes, 12-16 September 2011; Lisbon, Portugal
   Google Scholar
• Suzuki M, Honda K, Fukazawa M, Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 2012;341(3):692-701
   PubMed Web of Science ®Google Scholar
• Liang Y, Arakawa K, Ueta K, Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012;7(2):e30555
   PubMed Web of Science ®Google Scholar
• Zinker B, Ma X, Liu H, Acute glucose fluxes following a single dose of dapagliflozin [abstract 995-P]. 71st Scientific Sessions of the American Diabetes Association; 24-28 June 2011; San Diego, CA
   Google Scholar
• Takasu T, Tahara A, Yokono M, ASP1941, a novel, potent and selective SGLT2 inhibitor, improves hemoglobin A1c and symptoms of diabetes in animal models [abstract 562-P]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010, Oralando, FL
   Google Scholar
• Knight DR, Amin NB, Beebe DA, Sodium glucose co-transporter-2 (SGLT2), PF-04971729, reduces blood pressure and body weight in spontaneously hypertensive rats (SHR) [abstract 1105]. 47th Annual Meeting of the European Association for the Study of Diabetes; 12-16 September, 2011, Lisbon, Portugal
   Google Scholar
• Grempler R, Thomas L, Klein T, Weight loss induced by the potent and selective SGLT2 inhibitor, BI 10773, is due to body fat reduction. Studies in dietary-induced obese rats [abstract 1793]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010; Orlando, FL
   Google Scholar
• Uchida S, Takahashi K, Tomoike H, TS-071, a novel, potent and selective SGLT2 inhibitor, induces weight loss and a reduction in adipocyte size in diet-induced obese rats. [abstract 1000]. 71st Scientific Sessions of the American Diabetes Association; 24-28 June 2011; San Diego, CA
   Google Scholar
• Devenny JJ, Godonis HE, Harvey SJ, Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 2012;20(8):1645-52
   PubMed Web of Science ®Google Scholar
• Jurczak MJ, Lee HY, Birkenfeld AL, SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011;60(3):890-8
   PubMed Web of Science ®Google Scholar
• Ly JP, Onay T, Sison K, The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 2011;22(1):113-23
   PubMed Web of Science ®Google Scholar
• Vallon V, Platt KA, Cunard R, SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22(1):104-12
   PubMed Web of Science ®Google Scholar
• Nunoi K, Yasuda K, Adachi T, Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 2002;29(5-6):386-90
   PubMed Web of Science ®Google Scholar
• Jelsing J, Vrang N, Mark M, The sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin has a durable effect on the restoration of glucose homeostasis by preserving beta-cell mass in Zucker diabetic fatty rats. Diabetes 2012;61(Suppl):A261
   Google Scholar
• Macdonald FR, Peel JE, Jones HB, The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010;12(11):1004-12
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Schurmann A, Vallon V, Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012;61(1):187-96
   PubMed Web of Science ®Google Scholar
• Gribble FM, Williams L, Simpson AK, A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003;52(5):1147-54
   PubMed Web of Science ®Google Scholar
• Freiman J, Ruff D, Frazier K, LX4211, a dual SGLT2/SGLT1 inhibitor, shows rapid and significant improvement in glycemic control over 28 days in patients with type 2. diabetes [abstract 17-LB]. 70th Scientific Sessions of the American Diabetes Association, 25-29 June 2010, Orlando, FL
   Google Scholar
• Powell DR, Smith M, Zhao S, The combination of LX4211 and DPP-4 inhibition synergistically increases serum levels of active GLP-1 after oral glucose challenge in mice. Diabetes 2012;61(Suppl):A239
   Google Scholar
• Ogbaa I, Powell DR, Banks P, LX4211, a dual inhibitor of SGLT1 and SLGT2, results in postprandial glucose reductions in healthy subjects. Diabetes 2012;61(Suppl):A266
   Google Scholar
• Hussey EK, Clark RV, Amin DM, Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010;50(6):623-35
   PubMed Web of Science ®Google Scholar
• Hussey EK, Dobbins RL, Stoltz RR, Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol 2010;50(6):636-46
   PubMed Web of Science ®Google Scholar
• Kapur A, O'Connor-Semmes R, Hussey EK, First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus (T2DM) [abstract 509]. 69th Scientific Sessions of the American Diabetes Association; 5-9 June 2009; New Orleans, LA
   Google Scholar
• Mudaliar S, Henry RR, Boden G. Changes in insulin sensitivity as measured by glucose disposal rate and acute insulin secretion with the sodium glucose co-transporter inhibitor dapagliflozin [abstract 854]. Presented at: European Association for the Study of Diabetes; 12-16 September 2011
   Google Scholar
• Salsali A, Bastien A, Mansfield TA, Dapagliflozin improves hyperglycemia and beta-cell function without increasing hypoglycemic episodes in patients with type 2 diabetes mellitus. Presented at: American Association of Clinical Endocrinologists; 13-17 April 2011; San Diego, CA
   Google Scholar
• Bolinder J, Ljunggren O, Kullberg J, Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97(3):1020-31
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Lambers-Heerspink H, Boulton D, The SGLT2 inhibitor dapagliflozin, a proximal tubular diuretic with antihypertensive properties? World Congress of Nephrology, Vancouver, Canada; 2011
   Google Scholar
• Lambers-Heerspink H, de Zeeuw D, Wei L, Haemodynamic effects of dapagliflozin or hydrochlorothiazide in patients with type 2 diabetes mellitus [Abstract 305]. European Society of Cardiology Congress; 25-29 August 2012; Munich, Germany
   Google Scholar
• Veltkamp SA, Van Dijk J, Krauwinkel WJ, The effect of renal impairment on the pharmacokinetics and urinary glucose excretion of the SGLT2 inhibitor ASP1941 in type 2 diabetes mellitus patients [abstract 1127-P]. 71st Scientific Sessions of the American Diabetes Association; 24-28 June 2011; San Diego, CA
   Google Scholar
• Haneda M, Seino Y, Sasaki T, The effect of luseogluflozin (TS-071), a selective SGLT2 inhibitor, on pharmacodynamics and pharmacokinetics in Japanese type 2 diabetic subjects with renal impairment [abstract X18]. 71st Scientific Sessions of the American Diabetes Association; 8-12 June 2012; Philadelphia, PA
   Google Scholar
• Yale J-F, Bakris G, Xi L, Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves glycemia and is well tolerated in type 2 diabetes mellitus (T2DM) subjects with moderate renal impairment [abstract 41-LB]. 71st Scientific Sessions of the American Diabetes Association; 8-12 June 2012, Philadelphia, PA
   Google Scholar
• Kohan DE, Fioretto P, List JF, Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract TH-P0524]. American Society of Nephrology (ASN) Kidney Week 2011 Annual Meeting; 8-13 November 2011; Philadelphia, PA
   Google Scholar
• Ptaszynska A, Johnsson KM, Apanovitch AM, Safety of dapagliflozin in clinical trials for T2DM. Diabetes 2012;61(Suppl):A258
   PubMedGoogle Scholar
• Ptaszynska A, Chalamandaris A-G, Sugg J, Effect of dapagliflozin on renal function. Diabetes 2012;61(Suppl 1):A283. 1098-P
   Google Scholar
• Woerle HJ, Ferrannini E, Berk A, Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes [Abstract LB49]. Diabetes 2012;61(Suppl 1A):LB13
   Google Scholar
• Goto K, Kashiwagi A, Kazuta K, Ipragliflozin reduces A1C and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: ILLUMINATE study. Diabetes 2012;61(Suppl 1):A269. 1046-P
   Google Scholar
• Hirji I, Guo Z, Andersson SW, Incidence of urinary tract infection among patients with type 2 diabetes in the UK general practice research database (GPRD). J Diabetes Complications 2012;26(6):513-16
   PubMed Web of Science ®Google Scholar
• Hirji I, Andersson SW, Guo Z, Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 2012;26(6):501-5
   PubMed Web of Science ®Google Scholar
• Nicolle LE, Capuano G, Ways K, Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin 2012;28(7):1167-71
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Zhao Y, Ways K, Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012;28(7):1173-8
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32(4):650-7
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33(10):2217-24
   PubMed Web of Science ®Google Scholar
• Janssen. Janssen Briefing Information for the January 10, 2013 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334551.pdf
   Google Scholar
• Tucker ME; FDA Advisory Panel Supports Diabetes Drug Canagliflozin. Available from: http://www.medscape.com/viewarticle/777503
   Google Scholar
• Fukazawa M, Nagata T, Murao N, Compensatory effect of endogenous glucose production (EGP) after acute urinary glucose excretion (UGE) from selective SGLT2 inhibition with tofogliflozin (TOFO) or SGLT1/2 inhibition with phlorizin (PHZ) in normal and diabetic rats. Diabetes 2012;61(Suppl):A296
   Google Scholar
• Nagata T, Fukazawa M, Suzuki M, Selective SGLT2 inhibition by tofogliflozin (TOFO) reduces renal glucose reabsorption (RGR) only in hyperglycemic conditions but not in hypo- or euglycemic conditions in rats. Diabetes 2012;61(Suppl):A296
   Google Scholar
• Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012;61(9):2199-204
   PubMed Web of Science ®Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51(5):1145-9
   PubMed Web of Science ®Google Scholar
• Dobbins RL, O'Connor-Semmes R, Kapur A, Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab 2012;14(1):15-22
   PubMed Web of Science ®Google Scholar
• Komoroski B, Vachharajani N, Feng Y, Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85(5):513-19
   PubMed Web of Science ®Google Scholar
• Nomura S, Sakamaki S, Hongu M, Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53(17):6355-60
   PubMed Web of Science ®Google Scholar
• Schwartz S, Morrow L, Hompesch M, Canagliflozin improves glycemic control in subjects with type 2 diabetes (T2D) not optimally controlled on stable doses of insulin [abstract 564-P]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010; Orlando, FL
   Google Scholar
• Veltkamp SA, Kadokura T, Krauwinkel WJ, Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 2011;31(12):839-51
   PubMed Web of Science ®Google Scholar
• Veltkamp SA, Kadokura T, Krauwinkel WJ, ASP1941, a novel and selective SGLT2 inhibitor, stimulates urinary glucose excretion in healthy subjects [abstract 565-P]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010; Orlando, FL
   Google Scholar
• Heise T, Seewaldt-Becker E, Macha S, BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2) is safe and efficacious following 4-week treatment in patients with type 2 diabetes [abstract 629-P]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010; Orlando, FL
   Google Scholar
• Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010;53(8):3247-61
   PubMed Web of Science ®Google Scholar
• Sasaki T, Seino Y, Fukatsu A, TS-071, a novel potent and highly selective renal sodium-glucose co-transporter 2 (SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. [abstract 846]. 47th Annual Meeting of the European Association for the Study of Diabetes; 12-16 September 2011; Lisbon, Portugal
   Google Scholar
• Mascitti V, Maurer TS, Robinson RP, Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem 2011;54(8):2952-60
   PubMed Web of Science ®Google Scholar
• Nucci G, Amin NB, Wang X, The sodium glucose co-transporter 2 (SGLT2) inhibitor, PF-04971729, provides multi-faceted improvements in diabetic patients inadequately controlled on metformin [abstract 850]. 47th Annual Meeting of the European Association for the Study of Diabetes; 12-16 September 2011; Lisbon, Portugal
   Google Scholar
• Powell DR, Freiman J, Frazier K, Single doses of LX4211, a dual inhibitor of SGLT1 and SGLT2, improve parameters of glycemic control and increase GLP-1 and PYY in patients with type 2 diabetes (T2D) [abstract 982-P]. 71st Scientific Sessions of the American Diabetes Association; 24-28 June 2011; San Diego, CA
   Google Scholar
• Ohtake Y, Sato T, Kobayashi T, Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2012;55(17):7838-40
   Google Scholar
• Tahara A, Kurosaki E, Yokono M, Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 2012;385(4):423-36
   PubMed Web of Science ®Google Scholar
• Thomas L, Grempler R, Eckhardt M, Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab 2012;14(1):94-6
   PubMed Web of Science ®Google Scholar
• Chen L, Klein T, Leung PS. Combination of an SGLT2 inhibitor (BI 383335) with lingaliptin: beneficial effects on islet function and insulin sensitivity in db/db mice. Diabetes 2011;60(Suppl):A539
   Google Scholar
• Han S, Hagan DL, Taylor JR, Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57(6):1723-9
   PubMed Web of Science ®Google Scholar
• Zhang W, Welihinda A, Mechanic J, EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res 2011;63(4):284-93
   PubMed Web of Science ®Google Scholar
• Devenny JJ, Harvey SJ, Rooney S, The effect of dapagliflozin, a highly selective SGLT2 inhibitor, on bodyweight in diet-induced obese rats [abstract 0384]. The Obesity Society Annual Scientific Meeting; 20-24 October 2007; New Orleans, LA
   Google Scholar
• Luippold G, Klein T, Mark M, Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012;14(7):601-7
   PubMed Web of Science ®Google Scholar
• Katsuno K, Fujimori Y, Takemura Y, Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007;320(1):323-30
   PubMed Web of Science ®Google Scholar
• Takasu T, Hayashizaki Y, Hirosumi J, Ipragliflozin, a novel SGLT2-selective inhibitor, improves glycemic control and reduces body fat in the diabetic Goto-Kakizaki (GK) rats [abstract 1143-P]. Diabetes 2012;61:A294
   Google Scholar
• Hussey EK, Kapur A, O'Connor-Semmes R, Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate (SGLT2 inhibitor) and metformin when co-administered in type 2 diabetes mellitus (T2DM) patients [Abstract 582]. 69th Scientific Sessions of the American Diabetes Association; 5-9 June 2009; New Orleans, LA
   Google Scholar
• Komoroski B, Vachharajani N, Boulton D, Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85(5):520-6
   PubMed Web of Science ®Google Scholar
• Sarich T, Devineni D, Ghosh A, Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2), increases 24-h urinary glucose excretion and decreases body weight in obese subjects [abstract 567-P]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010; Orlando, FA
   Google Scholar
• Sasaki T, Seino Y, Fukatsu A, TS-071, a novel, potent and selective SGLT2 inhibitor, induced dose-related increase of urinary glucose excretion and showed good tolerability in Japanese healthy male subjects [abstract 1140-P]. 71st Scientific Sessions of the American Diabetes Association; 24-28 June 2011; San Diego, CA
   Google Scholar
• Port A, Macha S, Seman L, Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2) in healthy volunteers [abstract 569-P]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010, Orlando, FL
   Google Scholar
• Sha S, Devineni D, Ghosh A, Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated [abstract 568-P]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010; Orlando, FL
   Google Scholar
• Akiyama N, Kashiwagi A, Kadokura T, ASP1941, a novel, selective SGLT2 inhibitor improved both fasting and postprandial glucose levels in Japanese type 2 diabetic patients [abstract 1023-P]. 71st Scientific Sessions of the American Diabetes Association; 24-28 June 2011; San Diego, CA
   Google Scholar
• Seman L, Macha S, Jones P, Safety and tolerabilty of BI 10773, a sodium-glucose co-transporter (SGLT2) inhibitor, following 8 days treatment in patients with type 2 diabetes [abstract 571-P]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010, Orlando, FL
   Google Scholar
• Zambrowicz B, Freiman J, Brown PM, LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012;92(2):158-69
   PubMed Web of Science ®Google Scholar
• Schwartz S, Klasen S, Kowalski D, ASP1941, a novel and selective inhibitor of sodium glucose co-transporter 2 (SGLT2), reduces fasting plasma glucose in type 2 diabetes mellitus patients over 28 days [abstract 566-P]. 70th Scientific Sessions of the American Diabetes Association; 25-29 June 2010; Orlando, FL
   Google Scholar
• Amin NB, Wang X, Nucci G, The sodium glucose co-transporter 2 (SGLT2) inhibitor, PF-04971729 [abstract 844]. 47th Annual Meeting of the European Association for the Study of Diabetes; 12-16 September 2011; Lisbon, Portugal
   Google Scholar
• Kalgutkar AS, Tugnait M, Zhu T, Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos 2011;39(9):1609-19
   PubMed Web of Science ®Google Scholar
• Wilding JP, Norwood P, T'joen C, A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32(9):1656-62
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9733):2223-33
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Soler NG, Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012;156(6):405-15
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Rohwedder K, Long-term effectiveness of dapagliflozin over 104 weeks in patients with type 2 diabetes poorly controlled with insulin. Diabetes 2012;61(Suppl):A267
   PubMedGoogle Scholar
• Jabbour SA, Hardy E, Sugg J, Dapagliflozin as add-on therapy to sitagliptin with or without metformin: a randomized, double-blind, placebo-controlled study. Diabetes 2012;61(Suppl):A275
   Google Scholar
• Nauck MA, Del PS, Meier JJ, Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34(9):2015-22
   PubMed Web of Science ®Google Scholar
• Strojek K, Yoon KH, Hruba V, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13(10):928-38
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Vico M, Wei L, Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35(7):1473-8
   PubMed Web of Science ®Google Scholar
• Henry RR, Murray AV, Marmolejo MH, Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66(5):446-56
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Polidori D, Zhao Y, Canagliflozin, an inhibitor of sodium glucose co-transporter 2, improves glycaemic control, lowers body weight, and improves beta cell function in subjects with type 2 diabetes on background metformin [abstract 873]. 46th Annual Meeting of European Association for the Study of Diabetes; 20-24 September 2010; Stockholm, Sweden
   Google Scholar
• Wilding JP, Mathieu C, Vercruysse F, Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes inadequately controlled with metformin and sulfonylurea [Abstract 1022-P]. Diabetes 2012;61(Suppl 1):A262
   Google Scholar
• Cefalu WT, Leiter LA, Niskanen L, Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [abstract 38-LB]. Presented at: 72nd Scientific Sessions of the American Diabetes Association; 8-12 June 2012, Philadelphia, PA
   Google Scholar
• Gross JL, Schernthaner G, Fu M, Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulfonylurea [Abstract 50-LB]. Diabetes 2012;61(Suppl 1A):LB13
   Google Scholar
• Seino Y, Sasaki T, Fukatsu A, Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus. Diabetes 2012;61(Suppl 1):A266. 1039-P
   Google Scholar
• Silverman M, Turner JR. Glucose transport in the renal proximal tubule. Handbook of Physiology John Wiley & Sons, New York, NY; 1992. p. 2017-38
   Google Scholar